MEN1 tumorigenesis in the pituitary and pancreatic islet requires Cdk4 but not Cdk2
M P Gillam1, D Nimbalkar1, L Sun1
1Department of Molecular Pharmacology and Biological Chemistry, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Abstract:
Recent studies suggest that physiological and tumorigenic proliferation of mammalian cells is controlled by multiple cyclin-dependent kinases (CDKs) largely in tissue-specific manners. We and others previously demonstrated that adult mice deficient for the Cyclin D partner CDK4 (Cdk4(-/-) mice) exhibit hypoplasia in the pituitary and pancreatic islet due to primary postnatal defects in proliferation. Intriguingly, those neuroendocrine tissues affected in Cdk4(-/-) mice are the primary targets of tumorigenesis in the syndrome of multiple endocrine neoplasia type-1 (MEN1). Mice with heterozygous disruption of the tumor suppressor Men1 gene (Men1(+/-)) develop tumors in the pituitary, pancreatic islets and other neuroendocrine tissues, which is analogous to humans with MEN1 mutations. To explore the genetic interactions between loss of Men1 and activation of CDKs, we examined the impact of Cdk4 or Cdk2 disruption on tumorigenesis in Men1(+/-) mice. A majority of Men1(+/-) mice with wild-type CDKs developed pituitary and islet tumors by 15 months of age. Strikingly, Men1(+/-); Cdk4(-/-) mice did not develop any tumors, and their islets and pituitaries remained hypoplastic with decreased proliferation. In contrast, Men1(+/-); Cdk2(-/-) mice showed pituitary and islet tumorigenesis comparable to those in Men1(+/-) mice. Pituitaries of Men1(+/-); Cdk4(-/-) mice showed no signs of loss of heterozygosity (LOH) in the Men1 locus, whereas tumors in Men1(+/-) mice and Men1(+/-); Cdk2(-/-) mice exhibited LOH. Consistently, CDK4 knockdown in INS-1 insulinoma cells inhibited glucose-stimulated cell cycle progression with a significant decrease in phosphorylation of retinoblastoma protein (RB) at specific sites including Ser780. CDK2 knockdown had minimum effects on RB phosphorylation and cell cycle progression. These data suggest that CDK4 is a critical downstream target of MEN1-dependent tumor suppression and is required for tumorigenic proliferation in the pituitary and pancreatic islet, whereas CDK2 is dispensable for tumorigenesis in these neuroendocrine cell types.
Insights
Cyclin-dependent kinase 4 (CDK4) is essential for tumor development in the pituitary and pancreatic islet in mice with a disrupted Men1 gene. CDK4 acts as a critical downstream target for MEN1 tumor suppression, unlike CDK2.
Area of Science:
- Cell Biology
- Molecular Biology
- Cancer Research
Background:
- Mammalian cell proliferation, including tumorigenic growth, is regulated by multiple cyclin-dependent kinases (CDKs) in a tissue-specific manner.
- Mice lacking CDK4 (Cdk4(-/-)) exhibit hypoplasia in the pituitary and pancreatic islet, tissues targeted in Multiple Endocrine Neoplasia type 1 (MEN1).
- Men1(+/-) mice, analogous to human MEN1 mutations, develop tumors in these neuroendocrine tissues.
Purpose of the Study:
- To investigate the genetic interactions between Men1 loss and CDK activation in tumorigenesis.
- To determine the specific roles of CDK4 and CDK2 in the development of pituitary and pancreatic islet tumors in Men1(+/-) mice.
Main Methods:
- Examined the impact of Cdk4 or Cdk2 disruption on tumorigenesis in Men1(+/-) mice.
- Analyzed tumor development, proliferation, and loss of heterozygosity (LOH) at the Men1 locus.
- Utilized CDK4 and CDK2 knockdown in INS-1 insulinoma cells to assess effects on cell cycle progression and retinoblastoma protein (RB) phosphorylation.
Main Results:
- Men1(+/-); Cdk4(-/-) mice showed no tumor development; pituitaries and islets remained hypoplastic with reduced proliferation.
- Men1(+/-); Cdk2(-/-) mice exhibited tumorigenesis comparable to Men1(+/-) mice.
- CDK4 knockdown significantly inhibited cell cycle progression and RB phosphorylation, while CDK2 knockdown had minimal effects.
Conclusions:
- CDK4 is a critical downstream target of MEN1-dependent tumor suppression.
- CDK4 is required for tumorigenic proliferation in the pituitary and pancreatic islet.
- CDK2 is dispensable for tumorigenesis in these specific neuroendocrine cell types.
Related Concept Videos
Inhibition of Cdk Activity
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Positive Regulator Molecules
Abnormal Proliferation


